Published in Mol Biol Int on June 08, 2011
Leishmaniasis, malaria, and schistosomiasis concurrently in an 8-year-old boy. Saudi Med J (2015) 1.19
Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India. PLoS Negl Trop Dis (2012) 0.96
Strategies to overcome antileishmanial drugs unresponsiveness. J Trop Med (2014) 0.89
Drug resistance in leishmaniasis: Newer developments. Trop Parasitol (2014) 0.88
Immune regulation during chronic visceral leishmaniasis. PLoS Negl Trop Dis (2014) 0.88
The elements of life and medicines. Philos Trans A Math Phys Eng Sci (2015) 0.88
Intrachromosomal amplification, locus deletion and point mutation in the aquaglyceroporin AQP1 gene in antimony resistant Leishmania (Viannia) guyanensis. PLoS Negl Trop Dis (2015) 0.87
Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia. PLoS Negl Trop Dis (2014) 0.87
The Abl and Arg kinases mediate distinct modes of phagocytosis and are required for maximal Leishmania infection. Mol Cell Biol (2012) 0.86
Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1. PLoS Negl Trop Dis (2015) 0.86
Over-expression of 60s ribosomal L23a is associated with cellular proliferation in SAG resistant clinical isolates of Leishmania donovani. PLoS Negl Trop Dis (2013) 0.84
Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent. J Infect Dis (2012) 0.84
Quantification of Leishmania infantum kinetoplast DNA for monitoring the response to meglumine antimoniate therapy in visceral leishmaniasis. Am J Trop Med Hyg (2013) 0.81
Tyrosine aminotransferase from Leishmania infantum: A new drug target candidate. Int J Parasitol Drugs Drug Resist (2014) 0.78
Delivery of host cell-directed therapeutics for intracellular pathogen clearance. Expert Rev Anti Infect Ther (2013) 0.78
Metalloid compounds as drugs. Res Pharm Sci (2013) 0.78
Chemotherapeutic potential of 17-AAG against cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. PLoS Negl Trop Dis (2014) 0.78
Carboxylate derivatives of tributyltin (IV) complexes as anticancer and antileishmanial agents. Daru (2017) 0.78
Identification of Th1/Th2 regulatory switch to promote healing response during leishmaniasis: a computational approach. EURASIP J Bioinform Syst Biol (2015) 0.77
Evaluating aziridinyl nitrobenzamide compounds as leishmanicidal prodrugs. Antimicrob Agents Chemother (2013) 0.77
Evaluation of α,β-unsaturated ketones as antileishmanial agents. Antimicrob Agents Chemother (2015) 0.76
Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis. PLoS Negl Trop Dis (2015) 0.76
Naloxonazine, an Amastigote-Specific Compound, Affects Leishmania Parasites through Modulation of Host-Encoded Functions. PLoS Negl Trop Dis (2016) 0.76
A Comparative Study of Serum, Urine and Saliva Using rk39 Strip for the Diagnosis of Visceral Leishmaniasis. J Arthropod Borne Dis (2015) 0.76
The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy. Front Pharmacol (2017) 0.75
The impact of human immunodeficiency virus (HIV) co-infection on the economic burden of cutaneous leishmaniasis (CL) in Brazil and potential value of new CL drug treatments. Am J Trop Med Hyg (2014) 0.75
P-glycoprotein A Gene Expression in Glucantime-Resistant and Sensitive Leishmania major (MRHO/IR/75/ER). Iran J Parasitol (2014) 0.75
Tissue distribution of residual antimony in rats treated with multiple doses of meglumine antimoniate. Mem Inst Oswaldo Cruz (2014) 0.75
Inhibition of Src homology 2 domain-containing phosphatase 1 increases insulin sensitivity in high-fat diet-induced insulin-resistant mice. FEBS Open Bio (2016) 0.75
Biological Activity of Coumarin Derivatives as Anti-Leishmanial Agents. PLoS One (2016) 0.75
Zinc(II)-Dipicolylamine Coordination Complexes as Targeting and Chemotherapeutic Agents for Leishmania major. Antimicrob Agents Chemother (2016) 0.75
MAPK1 of Leishmania donovani modulates antimony susceptibility by downregulating P-glycoprotein efflux pumps. Antimicrob Agents Chemother (2015) 0.75
Molecular docking and molecular dynamics simulation study of inositol phosphorylceramide synthase - inhibitor complex in leishmaniasis: Insight into the structure based drug design. F1000Res (2016) 0.75
Coating doxorubicin-loaded nanocapsules with alginate enhances therapeutic efficacy against Leishmania in hamsters by inducing Th1-type immune responses. Br J Pharmacol (2014) 0.75
Eyelid Cutaneous Leishmaniasis: A Case Report. Iran J Public Health (2017) 0.75
Unusual Presentation of Cutaneous Leishmaniasis: Ocular Leishmaniasis. Case Rep Infect Dis (2017) 0.75
DETC-based bacterial cellulose bio-curatives for topical treatment of cutaneous leishmaniasis. Sci Rep (2016) 0.75
In vitro and in vivo leishmanicidal activity of Astronium fraxinifolium (Schott) and Plectranthus amboinicus (Lour.) Spreng against Leishmania (Viannia) braziliensis. Biomed Res Int (2014) 0.75
In vitro additive interaction between ketoconazole and antimony against intramacrophage Leishmania (Leishmania) amazonensis amastigotes. PLoS One (2017) 0.75
Historical and biochemical aspects of a seventeenth century gold-based aurum vitae recipe. J Biol Inorg Chem (2014) 0.75
Evidence for Tissue Toxicity in BALB/c Exposed to a Long-Term Treatment with Oxiranes Compared to Meglumine Antimoniate. Biomed Res Int (2017) 0.75
Glutathione. Annu Rev Biochem (1983) 15.18
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis (2002) 7.17
Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 6.20
Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol (1990) 5.87
Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev (1997) 4.09
Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med (2007) 3.74
Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis (2000) 3.72
Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol (1992) 3.57
Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest (1993) 3.28
Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol (2003) 3.17
Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health (2001) 3.08
Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis (1999) 2.92
In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest (1993) 2.84
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis (2007) 2.74
Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med (1999) 2.51
Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol (2003) 2.41
Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev (2005) 2.33
A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis (2006) 2.29
Microtubules and signal transduction. Curr Opin Cell Biol (1999) 2.21
Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem (1994) 2.19
Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ (1998) 2.15
P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J Biol Chem (1995) 2.12
Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis (1988) 2.11
An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. Mol Biochem Parasitol (2003) 2.07
Chemotherapy of leishmaniasis. Curr Pharm Des (2002) 2.04
Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol (1991) 2.00
Vanadium in cancer treatment. Crit Rev Oncol Hematol (2002) 1.89
Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem (2004) 1.86
Vanadium compounds as insulin mimics. Chem Rev (1999) 1.84
Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother (1997) 1.83
Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc Natl Acad Sci U S A (1996) 1.74
Direct and inverted DNA repeats associated with P-glycoprotein gene amplification in drug resistant Leishmania. EMBO J (1991) 1.74
In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother (1997) 1.67
Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest (1989) 1.67
Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg (1984) 1.62
Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem (2007) 1.62
Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother (2004) 1.60
Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. J Biol Chem (2004) 1.60
Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. Biochim Biophys Acta (2008) 1.58
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat (2006) 1.58
A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am J Trop Med Hyg (2004) 1.57
Combination therapy in Kala-azar. J Assoc Physicians India (1995) 1.54
Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J Biol Chem (2000) 1.54
Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ (2005) 1.53
Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis (1992) 1.53
Drug resistance in leishmaniasis. J Glob Infect Dis (2010) 1.52
New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis (2008) 1.51
Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg (2004) 1.51
Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials. Eur J Biochem (1995) 1.50
Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol (2007) 1.50
In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob Agents Chemother (1995) 1.49
Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J (1997) 1.49
The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J Biol Chem (2001) 1.48
Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother (2006) 1.48
Ovothiol and trypanothione as antioxidants in trypanosomatids. Mol Biochem Parasitol (2001) 1.46
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother (2006) 1.46
Transport and detoxification systems for transition metals, heavy metals and metalloids in eukaryotic and prokaryotic microbes. Comp Biochem Physiol A Mol Integr Physiol (2002) 1.45
Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun (2000) 1.44
Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother (1998) 1.44
An ATP-dependent As(III)-glutathione transport system in membrane vesicles of Leishmania tarentolae. Proc Natl Acad Sci U S A (1996) 1.44
Pentavalent antimonials: new perspectives for old drugs. Molecules (2009) 1.43
Leishmania EF-1alpha activates the Src homology 2 domain containing tyrosine phosphatase SHP-1 leading to macrophage deactivation. J Biol Chem (2002) 1.42
Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann Trop Med Parasitol (1992) 1.41
Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol Microbiol (1999) 1.40
Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis (2007) 1.39
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents (2007) 1.39
Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J Antimicrob Chemother (2007) 1.38
A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health (2001) 1.37
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res (2005) 1.36
Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol (2005) 1.35
Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. J Infect Dis (1988) 1.35
Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrob Agents Chemother (2005) 1.34
Antimonial-induced increase in intracellular Ca2+ through non-selective cation channels in the host and the parasite is responsible for apoptosis of intracellular Leishmania donovani amastigotes. J Biol Chem (2003) 1.32
Leishmania mexicana: chemistry and biochemistry of sodium stibogluconate (Pentostam). Exp Parasitol (1988) 1.32
Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol (2000) 1.32
High level arsenite resistance in Leishmania tarentolae is mediated by an active extrusion system. Mol Biochem Parasitol (1994) 1.31
Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. J Infect Dis (2000) 1.31
Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg (1985) 1.31
Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem J (2004) 1.30
Role and effect of IL-2 in experimental visceral leishmaniasis. J Immunol (1993) 1.29
Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob Agents Chemother (2003) 1.29
Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate. Antimicrob Agents Chemother (2001) 1.29
Multiple drug resistance and conservative amplification of the H region in Leishmania major. J Biol Chem (1989) 1.28
Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg (2007) 1.28
Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-gamma-triggered JAK2 activation. Eur J Immunol (1999) 1.27
Comparison of regimens of treatment with sodium stibogluconate in kala-azar. Br Med J (Clin Res Ed) (1984) 1.27
Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione. Biometals (2003) 1.27
Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. Br Med J (Clin Res Ed) (1988) 1.27
Inhibition of leishmanias but not host macrophages by the antitubulin herbicide trifluralin. Science (1990) 1.26
Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother (1999) 1.25
Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis (2009) 1.25
Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant Leishmania tarentolae. Mol Biochem Parasitol (2000) 1.24
Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother (2005) 1.24
Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob Agents Chemother (1985) 1.22
Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Ann Trop Med Parasitol (1998) 1.22
Efflux systems and increased trypanothione levels in arsenite-resistant Leishmania. Exp Parasitol (1997) 1.20
Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem Pharmacol (1987) 1.20
Evaluation of a urinary antigen-based latex agglutination test in the diagnosis of kala-azar in eastern Nepal. Trop Med Int Health (2004) 1.20
Leishmania donovani targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection. Cell Host Microbe (2013) 1.77
Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. Sci Transl Med (2014) 1.57
Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother (2006) 1.48
MerTK is required for apoptotic cell-induced T cell tolerance. J Exp Med (2008) 1.48
Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. J Immunol (2002) 1.35
Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity. Blood (2004) 1.35
Leishmania donovani suppresses activated protein 1 and NF-kappaB activation in host macrophages via ceramide generation: involvement of extracellular signal-regulated kinase. Infect Immun (2002) 1.32
Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts. J Immunol (2005) 1.28
Immunoregulation of dendritic cells. Clin Med Res (2005) 1.23
Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells. Infect Immun (2009) 1.15
Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection. Antimicrob Agents Chemother (2007) 1.15
Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. Int J Parasitol (2011) 1.10
Chemokine-induced leishmanicidal activity in murine macrophages via the generation of nitric oxide. J Infect Dis (2002) 1.08
Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology. PLoS One (2006) 1.08
EBV latent membrane protein 2A induces autoreactive B cell activation and TLR hypersensitivity. J Immunol (2006) 1.07
Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. Proc Natl Acad Sci U S A (2013) 1.07
Leishmania donovani isolates with antimony-resistant but not -sensitive phenotype inhibit sodium antimony gluconate-induced dendritic cell activation. PLoS Pathog (2010) 1.03
HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J Infect Dis (2007) 1.01
Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens? Crit Rev Microbiol (2012) 1.01
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype? Expert Rev Anti Infect Ther (2014) 1.00
Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani. Parasitol Res (2012) 1.00
Restoration of IFNγR subunit assembly, IFNγ signaling and parasite clearance in Leishmania donovani infected macrophages: role of membrane cholesterol. PLoS Pathog (2011) 0.99
Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol. J Lipid Res (2012) 0.97
A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo. BMC Cancer (2006) 0.95
Vaccination with leishmania hemoglobin receptor-encoding DNA protects against visceral leishmaniasis. Sci Transl Med (2013) 0.92
Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure. Mol Microbiol (2013) 0.91
KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine (2009) 0.91
Arabinosylated lipoarabinomannan skews Th2 phenotype towards Th1 during Leishmania infection by chromatin modification: involvement of MAPK signaling. PLoS One (2011) 0.89
Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Infect Immun (2007) 0.86
The lignan niranthin poisons Leishmania donovani topoisomerase IB and favours a Th1 immune response in mice. EMBO Mol Med (2012) 0.85
TGF-β-regulated tyrosine phosphatases induce lymphocyte apoptosis in Leishmania donovani-infected hamsters. Immunol Cell Biol (2010) 0.84
Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent. J Infect Dis (2012) 0.84
Immunomodulatory effects of antileishmanial drugs. J Antimicrob Chemother (2013) 0.84
Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection. PLoS Negl Trop Dis (2012) 0.84
Regulation of impaired protein kinase C signaling by chemokines in murine macrophages during visceral leishmaniasis. Infect Immun (2005) 0.83
A novel role for Bruton's tyrosine kinase in hepatocyte growth factor-mediated immunoregulation of dendritic cells. J Biol Chem (2011) 0.83
RFLPs of ITS, ITS1 and hsp70 amplicons and sequencing of ITS1 of recent clinical isolates of Kala-azar from India and Bangladesh confirms the association of L. tropica with the disease. Acta Trop (2012) 0.82
TGF-β1 re-programs TLR4 signaling in L. donovani infection: enhancement of SHP-1 and ubiquitin-editing enzyme A20. Immunol Cell Biol (2011) 0.82
Hepatocyte growth factor-induced c-Src-phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway inhibits dendritic cell activation by blocking IκB kinase activity. Int J Biochem Cell Biol (2011) 0.81
Activation of macrophages and lymphocytes by methylglyoxal against tumor cells in the host. Int Immunopharmacol (2008) 0.81
Role of chemokines in Leishmania infection. Curr Mol Med (2004) 0.79
Identification of new antigens in visceral leishmaniasis by expression cloning and immunoblotting with sera of kala-azar patients from Bihar, India. Infect Immun (2005) 0.79
Liposomal cholesterol delivery activates the macrophage innate immune arm to facilitate intracellular Leishmania donovani killing. Infect Immun (2013) 0.78
Cholesterol lowering drug may influence cellular immune response by altering MHC II function. J Lipid Res (2013) 0.78
Characterization of the recent clinical isolates of Indian Kala-azar patients by RAPD-PCR method. J Parasit Dis (2011) 0.78
Evidence of direct interactions between the CC-chemokines CCL3, CCL4 and CCL5 and Leishmania promastigotes. Mol Biochem Parasitol (2006) 0.77
Radio-attenuated leishmanial parasites as immunoprophylactic agent against experimental murine visceral leishmaniasis. Exp Parasitol (2011) 0.77
Therapeutic immunization with radio-attenuated Leishmania parasites through i.m. route revealed protection against the experimental murine visceral leishmaniasis. Parasitol Res (2012) 0.77
Carrier protein influences immunodominance of a known epitope: implication in peptide vaccine design. Vaccine (2013) 0.76
Sphingolipid-mediated restoration of Mitf expression and repigmentation in vivo in a mouse model of hair graying. Pigment Cell Melanoma Res (2009) 0.76
Correction: Leishmania donovani Infection Enhances Lateral Mobility of Macrophage Membrane Protein Which Is Reversed by Liposomal Cholesterol. PLoS Negl Trop Dis (2016) 0.75